TY - JOUR
T1 - Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy
AU - Inomata, Minehiko
AU - Hirai, Takahiro
AU - Seto, Zenta
AU - Tokui, Kotaro
AU - Taka, Chihiro
AU - Okazawa, Seisuke
AU - Kambara, Kenta
AU - Ichikawa, Tomomi
AU - Imanishi, Shingo
AU - Yamada, Toru
AU - Miwa, Toshiro
AU - Hayashi, Ryuji
AU - Tobe, Kazuyuki
N1 - Publisher Copyright:
© 2018, Arányi Lajos Foundation.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - We explored the associations between progression-free survival (PFS) after the initiation of PD-1 inhibitor therapy and the clinical parameters in patients with NSCLC. We reviewed the clinical data of patients with NSCLC treated with PD-1 inhibitor. Data of a total of 36 patients, including 16 patients with squamous cell NSCLC and 20 patients with non-squamous cell NSCLC were reviewed. Multivariate analyses identified EGFR status, C-reactive protein (CRP), and PFS following previous therapy as being significantly associated with the PFS after initiation of PD-1 inhibitor therapy in patients with NSCLC. In patients with squamous cell NSCLC, the blood neutrophil/lymphocyte ratio (NLR), serum lactate dehydrogenase (LDH), serum C-reactive protein (CRP), and PFS following previous therapy were identified as being significantly associated with the PFS after initiation of PD-1 inhibitor therapy. However, none of these associations, except for PFS following previous therapy, were found in patients with non-squamous cell NSCLC. NLR, LDH and CRP were associated with the PFS after initiation of PD-1 inhibitor therapy in patients with squamous cell NSCLC, and PFS following previous therapy was the common parameter associated with the PFS after initiation of PD-1 inhibitor therapy in both squamous-cell NSCLC and non-squamous-cell NSCLC patients.
AB - We explored the associations between progression-free survival (PFS) after the initiation of PD-1 inhibitor therapy and the clinical parameters in patients with NSCLC. We reviewed the clinical data of patients with NSCLC treated with PD-1 inhibitor. Data of a total of 36 patients, including 16 patients with squamous cell NSCLC and 20 patients with non-squamous cell NSCLC were reviewed. Multivariate analyses identified EGFR status, C-reactive protein (CRP), and PFS following previous therapy as being significantly associated with the PFS after initiation of PD-1 inhibitor therapy in patients with NSCLC. In patients with squamous cell NSCLC, the blood neutrophil/lymphocyte ratio (NLR), serum lactate dehydrogenase (LDH), serum C-reactive protein (CRP), and PFS following previous therapy were identified as being significantly associated with the PFS after initiation of PD-1 inhibitor therapy. However, none of these associations, except for PFS following previous therapy, were found in patients with non-squamous cell NSCLC. NLR, LDH and CRP were associated with the PFS after initiation of PD-1 inhibitor therapy in patients with squamous cell NSCLC, and PFS following previous therapy was the common parameter associated with the PFS after initiation of PD-1 inhibitor therapy in both squamous-cell NSCLC and non-squamous-cell NSCLC patients.
KW - Non-small cell lung cancer
KW - Programmed death 1 inhibitor
KW - Squamous cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85053551496&partnerID=8YFLogxK
U2 - 10.1007/s12253-018-0473-x
DO - 10.1007/s12253-018-0473-x
M3 - 学術論文
C2 - 30232703
AN - SCOPUS:85053551496
SN - 1219-4956
VL - 26
SP - 327
EP - 333
JO - Pathology and Oncology Research
JF - Pathology and Oncology Research
IS - 1
ER -